Effect of Androgen-Deprivation Therapy on Systemic Symptomatology in Men With Prostate Cancer

Description

Men undergoing androgen-deprivation therapy (ADT) for prostate cancer often experience symptoms of fatigue, depression, and cognitive impairment. Recent preliminary research published in Cancer examines markers of inflammation that may be associated with systemic symptomatology, including worsening fatigue, depressive symptoms, or cognitive impairment. The investigators found, however, that treatment-related increases in interleukin-6 (IL-6) were linked to increases in fatigue but not depressive or cognitive symptoms. These findings reported by Aasha Hoogland, PhD, of the Moffitt Cancer Center in Tampa, and colleagues may provide insight into improving quality of life for men with prostate cancer.